GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Price-to-Owner-Earnings

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Price-to-Owner-Earnings : 24.95 (As of Apr. 28, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Price-to-Owner-Earnings?

As of today (2024-04-28), Chugai Pharmaceutical Co's share price is $32.43. Chugai Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Mar. 2024 was $1.30. It's Price-to-Owner-Earnings for today is 24.95.


The historical rank and industry rank for Chugai Pharmaceutical Co's Price-to-Owner-Earnings or its related term are showing as below:

CHGCF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.66   Med: 60.04   Max: 6250
Current: 24.97

During the past 13 years, the highest Price-to-Owner-Earnings of Chugai Pharmaceutical Co was 6250.00. The lowest was 19.66. And the median was 60.04.


CHGCF's Price-to-Owner-Earnings is ranked better than
55.34% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs CHGCF: 24.97

As of today (2024-04-28), Chugai Pharmaceutical Co's share price is $32.43. Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $1.36. Therefore, Chugai Pharmaceutical Co's PE Ratio for today is 23.78.

As of today (2024-04-28), Chugai Pharmaceutical Co's share price is $32.43. Chugai Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in was $1.36. Therefore, Chugai Pharmaceutical Co's PE Ratio without NRI for today is 23.78.

During the past 13 years, Chugai Pharmaceutical Co's highest PE Ratio without NRI was 55.01. The lowest was 14.06. And the median was 33.90.


Chugai Pharmaceutical Co Price-to-Owner-Earnings Historical Data

The historical data trend for Chugai Pharmaceutical Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Price-to-Owner-Earnings Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.43 90.69 36.72 41.29 22.02

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.50 35.80 39.62 22.02 29.65

Competitive Comparison of Chugai Pharmaceutical Co's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Chugai Pharmaceutical Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Chugai Pharmaceutical Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=32.43/1.30
=24.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Chugai Pharmaceutical Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines